Germinoma medical therapy

Germinoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Epidemiology and Demographics
Risk Factors
Screening
Differentiating Germinoma from other Diseases
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Germinoma medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Germinoma medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA onGerminoma medical therapy
CDC on Germinoma medical therapy
Germinoma medical therapy in the news
on Germinoma medical therapy
Directions to Hospitals Treating Germinoma
Risk calculators and risk factors for Germinoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]

Overview

Therefore, radiation therapy remains an important and integral part of therapy for patients with CNS GCTs.

Medical Therapy

Radiation

• Germinomas are highly responsive to radiation therapy; however NGGCTs are less radiosensitive than pure germinomas.
• Since studies comparing full-dose craniospinal irradiation CSI with reduced-volume radiation, whether whole-ventricular or whole-brain have shown no significant difference in the pattern of relapse in germinomas, therefore, CSI is no longer used for localized germinomas.
• Trials to determine the best regimen for radiation therapy are still ongoing.
• Since patients who received radiation therapy to the localized tumor alone had a higher rate of recurrence, radiation therapy to include the whole ventricles is recommended.
• The majority of clinicians advocate a boost to the primary tumor bed in order to prevent local recurrence.
• Studies to prove the efficacy of radiation therapy alone versus neoadjuvant chemotherapy followed by response-based radiotherapy are currently under way. The use of intensive chemotherapy alone without radiation therapy has proven less effective compared with chemotherapeutic regimens and radiation therapy together.
• In patients with pure CNS germinomas, no deterioration in neurocognitive function and no compromise in outcome was found when chemotherapy was administered followed by reduced dose radiation therapy.

Treatment of patients with germinomas

• In patients with germinomas, neoadjuvant therapy prior to lower-dose and lower-volume radiation therapy is recommended. Germinomas are chemosensitive, specifically to platinum based agents. To permit the use of a lower radiation dose in patients with germinomas, chemotherapy has been recently added to the treatment regimen. This neoadjuvant therapy reduces the long-term morbidity associated with radiation therapy while maintaining the excellent survival rates.

Treatment of patients with nongerminomatous germ cell tumors

• Combined therapy with adjuvant and neoadjuvant chemotherapy with radiation therapy is intended to improve outcome in patients with NGGCTs. When compared with patients with germinomas, patients with NGGCTs have an inferior outcome. The role of full-dose craniospinal irradiation CSI is controversial in patients with localized NGGCTs. The agents that have shown the best activity against CNS GCTs are cisplatin, etoposide, vinblastine, bleomycin, and carboplatin. Ifosfamide and cyclophosphamide are also used. Therapy may be based on classification of CNS GCTs into good prognosis, intermediate prognosis, and poor prognosis. Patients with progressive or relapsed disease, especially those with NGGCTs, have a poor prognosis. In this group of patients high-dose chemotherapy followed by autologous stem cell transplant may be effective.

Treatment options in CNS germ cell tumors is shown below in a tabular form:

Stage or Tumor Type	Treatment Options
Newly diagnosed childhood germinomas	Radiation therapy Neoadjuvant chemotherapy followed by response-based radiation therapy
Newly diagnosed childhood teratomas	Surgery Adjuvant therapy, for patients who had a subtotal resection (controversial): Focal radiation therapy Chemotherapy Stereotactic radiosurgery
Newly diagnosed childhood nongerminomatous GCTs	Chemotherapy followed by radiation therapy Surgery
Recurrent childhood CNS GCTs	Chemotherapy followed by radiation therapy High-dose chemotherapy with stem cell rescue

Chemotherapeutic agents, which are used to treat germinomas and desmopressin acetate, which is used for the treatment of diabetes insipidus are shown below in a tabular form:

Drug name	Mechanism of action
Cisplatin	Cisplatin inhibits DNA synthesis and, thus, cell proliferation by causing DNA cross-links and denaturation of double helix
Bleomycin	Bleomycin is a glycopeptide antibiotic that inhibits DNA synthesis. For palliation in management of several neoplasms.
Etoposide, VP-16	Inhibits topoisomerase II and causes DNA strand breakage, causing cell proliferation to arrest in late S or early G2 phase of cell cycle.
Cyclophosphamide	It is chemically related to nitrogen mustards. As alkylating agent, mechanism of action of active metabolites may involve cross-linking of DNA, which may interfere with growth of normal and neoplastic cells
Desmopressin acetate	Increases cellular permeability of collecting ducts, resulting in reabsorption of water by kidneys.

References

Template:WikiDoc Sources